Previous 10 | Next 10 |
On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...
Shares of Stealth BioTherapeutics (NASDAQ: MITO) are up 9.8% at 1:11 p.m. EDT, having been up as much as 35%, following the announcement that the biotech gave Alexion Pharmaceuticals (NASDAQ: ALXN) an option to license elamipretide, Stealth's late-stage drug candidate for mitochondrial d...
Ra Pharmaceuticals (NASDAQ: RARX ) +102% on being acquired by UCB SA. More news on: Ra Pharmaceuticals, Inc., OncoSec Medical Incorporated, Bed Bath & Beyond Inc., Stocks on the move, Read more ...
Alexion Pharmaceuticals (NASDAQ: ALXN ) inks an agreement with Stealth BioTherapeutics (NASDAQ: MITO ) securing an option to co-develop and commercialize elamipretide for mitochondrial diseases. More news on: Alexion Pharmaceuticals, Inc., Stealth BioTherapeutics Corp, Healthcare stocks ...
- Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license - - Stealth to receive initial payment o...
BOSTON , Oct. 7, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the presentation of pre-cl...
BOSTON , Oct. 1, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy ...
Gainers: Dova Pharmaceuticals (NASDAQ: DOVA ) +38% . USA Technologies ( OTC:USAT ) +28% . Farmmi (NASDAQ: FAMI ) +24% . Thor Industries (NYSE: THO ) +21% . GTT Communications (NYSE: GTT ) +15% . Patrick Industries (NASDAQ: PATK ) +12% . Seattle Genetics (NASDAQ: SGEN ) +10% . ...
Arcus Biosciences (NYSE: RCUS ) initiated with Buy rating and $22 (150% upside) price target at Mizuho Securities. More news on: Arcus Biosciences, Inc., Stealth BioTherapeutics Corp, HOOKIPA Pharma Inc., Healthcare stocks news, Stocks on the move, , Read more ...
BOSTON , Sept. 20, 2019 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that management will...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...